Shamburg News · 8-K filed Nov 16, 2026, 7:45 AM EST
Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ at SNO 2026
CNSY · CERENOME, INC.
- Other event
- Reg FD disclosure
- Materiality: medium
On November 16, 2026, Cerenome, Inc. issued a press release reporting interim data from its ReSPECT-LM study of repeated intraventricular dosing of REYOBIQ in leptomeningeal metastases, presented as a poster at the 2026 SNO Annual Meeting on November 13, 2026. The company reported no dose-limiting toxicities in the first 10 patients and no LM progression among evaluable patients at the three- and six-month landmarks (0/5 at each), with progression in 1 of 4 evaluable patients by nine months. The findings are described by the company as preliminary, and the press release is furnished as Exhibit 99.1.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-462116.
Written from the filing by Shamburg Markets. Figures are as reported by the company.